Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data
Authors:
- Renato de Carvalho BarrosRBRenato de Carvalho Barros
- Vinícius C. FiusaVFVinícius C. Fiusa
- Gabrielle N. TimGTGabrielle N. Tim
- Victoria T. V. GoulartVGVictoria T. V. Goulart
- Caio Henrique M. NascimentoCNCaio Henrique M. Nascimento
- Gustavo T. de MouraGMGustavo T. de Moura
- Adriana J. B. A. GuimarãesAGAdriana J. B. A. Guimarães
- Sergio Henrique Rodolpho RamalhoSRSergio Henrique Rodolpho Ramalho
- Armindo Jreige Jr.AJArmindo Jreige Jr.
- Filipe A. MouraFMFilipe A. Moura
- Luiz Sérgio Fernandes de CarvalhoLCLuiz Sérgio Fernandes de Carvalho
Open Access
- 1 January 2026
- journal article
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Abstract
Background: Sacubitril/valsartan reduced mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril in pivotal clinical trials. However, real-world data under optimized dosing remain limited. Objective: To compare the outcomes of HFrEF patients treated with sacubitril/valsartan versus either enalapril or losartan at guideline-recommended maximum dosages. Methods: We analyzed data from an observational heart failure cohort (n = 2,314) including patients receiving care between August 2010 and September 2024 at six public hospitals in a large metropolitan area. The primary analysis included 254 HFrEF patients receiving the guideline-recommended maximum dosages of the investigated drugs. A sensitivity analysis included 452 patients receiving any submaximal dosages. The primary outcome was combined hospitalization or death. Baseline differences were adjusted using propensity score matching. A p-value < 0.05 was considered significant. Results: Among 254 HFrEF patients (mean age 63.6 ± 12.3 years, 61.4% male), 115 received sacubitril/valsartan 97/103mg twice daily, 33 enalapril 20 mg twice daily, and 106 losartan 100 mg daily. Over the median follow-up of 23.9 months (interquartile range 11.9–41.1), there were 70 primary endpoint events (56 first hospitalizations, 32 deaths). Compared to equivalent dosages of enalapril or losartan, sacubitril/valsartan was not associated with significant reductions in combined hospitalization or death (odds ratio 0.650, 95% confidence interval 0.354–1.195, p = 0.165), but it was associated with functional status improvement (odds ratio 3.902, 95% confidence interval 1.745–8.726, p = 0.001). Conclusion: This real-world study did not demonstrate significant reductions in hospitalization or mortality for sacubitril/valsartan compared with enalapril or losartan at guideline-recommended maximum dosages; however, sacubitril/valsartan was associated with improved functional status.Keywords
This publication has 10 references indexed in Scilit:
- Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trialsEuropean Journal of Clinical Pharmacology, 2024
- Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HFJournal of Cardiac Failure, 2024
- Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart FailureJACC, 2023
- Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial InfarctionNew England Journal of Medicine, 2021
- Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection FractionJAMA Cardiology, 2021
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2021
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart FailureNew England Journal of Medicine, 2019
- Neprilysin Inhibitors: Emerging Therapy for Heart FailureAnnual Review of Medicine, 2017
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- The Natural History of Congestive Heart Failure: The Framingham StudyNew England Journal of Medicine, 1971